Exploiting microRNAs as circulating biomarkers and regulators of key targetable proteins to combat cancer chemoresistance
The limited availability of effective treatments and the generally poor prognosis associated w ith many cancer types highlight the pressing need for novel therapeut ic approaches and new directions in chemoresistance research. Accordi ngly, this thesis aims to elucidate the mechanisms driving the develo pment of chemoresistance and to identify potential vulnerabilities th at may be exploited to improve the effectiveness of chemotherapy. Spe cifically, this work examines the role of microRNAs (miRNAs) in thera py resistance and evaluates their potential as diagnostic, prognostic , and predictive biomarkers in head and neck squamous cell carcinoma (HNSCC), pancreatic ductal adenocarcinoma (PDAC), and non-small cell lung cancer (NSCLC). Chapter 2 reviews the current knowledge of miRNA s in HNSCC, focusing on their roles in tumorigenesis and therapeutic potential. Chapter 3 reports novel findings on the oncogenic role of miR-96-5p in HNSCC and its contribution to resistance to chemotherapy and radiotherapy. Chapter 4 reviews recent advances and challenges i n the use of EVs as biomarker and therapeutic delivery systems. Chapt er 5 reports novel findings on plasma-derived EV miR-200 family membe rs and evaluates their diagnostic potential in PDAC. Chapter 6 focuse s on microRNAs implicated in resistance to gemcitabine and FOLFIRINOX in pancreatic ductal adenocarcinoma (PDAC) and examines miRNA-based therapeutic approaches. Chapter 7 investigates the therapeutic potent ial of combining tivantinib, a c-MET inhibitor, with gemcitabine in P DAC. Chapter 8 reviews emerging treatment strategies for small cell l ung cancer that extend beyond immunotherapy. Chapter 9 examines the m echanisms underlying resistance to the nucleoside analog RX-3117 in l ung cancer and proposes approaches to improve its therapeutic efficac y.
More information on the thesis
DESCRIPTION: Exploiting microRNAs as circulating biomarkers and regula tors of key targetable proteins to combat cancer chemoresistance The limited availability of effective treatments and the generally poor p rognosis associated with many cancer types highlight the pressing nee d for novel therapeutic approaches and new directions in chemoresista nce research. Accordingly, this thesis aims to elucidate the mechanis ms driving the development of chemoresistance and to identify potenti al vulnerabilities that may be exploited to improve the effectiveness of chemotherapy. Specifically, this work examines the role of microR NAs (miRNAs) in therapy resistance and evaluates their potential as d iagnostic, prognostic, and predictive biomarkers in head and neck squ amous cell carcinoma (HNSCC), pancreatic ductal adenocarcinoma (PDAC) , and non-small cell lung cancer (NSCLC). Chapter 2 reviews the curre nt knowledge of miRNAs in HNSCC, focusing on their roles in tumorigen esis and therapeutic potential. Chapter 3 reports novel findings on t he oncogenic role of miR-96-5p in HNSCC and its contribution to resis tance to chemotherapy and radiotherapy. Chapter 4 reviews recent adva nces and challenges in the use of EVs as biomarker and therapeutic de livery systems. Chapter 5 reports novel findings on plasma-derived EV miR-200 family members and evaluates their diagnostic potential in P DAC. Chapter 6 focuses on microRNAs implicated in resistance to gemci tabine and FOLFIRINOX in pancreatic ductal adenocarcinoma (PDAC) and examines miRNA-based therapeutic approaches. Chapter 7 investigates t he therapeutic potential of combining tivantinib, a c-MET inhibitor, with gemcitabine in PDAC. Chapter 8 reviews emerging treatment strate gies for small cell lung cancer that extend beyond immunotherapy. Cha pter 9 examines the mechanisms underlying resistance to the nucleosid e analog RX-3117 in lung cancer and proposes approaches to improve it s therapeutic efficacy.More information on the thesis END:VEVENT END:VCALENDAR